Sacituzumab govitecan for mesothelioma after prior treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a drug called sacituzumab govitecan (a targeted therapy that delivers chemotherapy directly to cancer cells) for people with mesothelioma that has already been treated with other therapies. The goal is to see if the drug can shrink tumors and help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of mesothelioma called diffuse pleural mesothelioma (cancer of the lining of your lung).
- You have already received at least one previous treatment for your cancer, like chemotherapy or immunotherapy.
- You are willing to have two small tissue samples (biopsies) taken from your tumor, if it is safe for you.
- You are generally active and able to take care of yourself (ECOG score 0 or Karnofsky score of 70% or more).
- Your blood tests, kidney, and liver function are within a certain range to safely receive the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—sacituzumab govitecan and cisplatin—for women with ovarian or endometrial cancer that has come back after responding to platinum chemotherapy. The goal is to see if the combination works better than current options.
This trial tests a combination of two drugs—sacituzumab govitecan and cetuximab—for people with advanced head and neck cancer that has gotten worse after immunotherapy. The goal is to see if this new treatment can shrink or slow the cancer.
This trial tests a drug called sacituzumab govitecan for people with advanced thymic cancer (thymoma or thymic carcinoma) that has not responded to previous treatments. The goal is to see if the drug can shrink or slow the growth of the cancer.
This Phase 1 study tests how safe and tolerable sacituzumab govitecan is for people with advanced or metastatic solid tumors who also have moderate liver impairment. It aims to find the right dosing so the treatment can be used more safely in this liver-risk group.
This study tests a drug called sacituzumab govitecan for people with metastatic colorectal cancer who have already tried several standard treatments. It may be an option if your cancer is not MSI-H or dMMR and you haven't had irinotecan recently.
This Phase 2 trial tests sacituzumab govitecan, an anti-cancer medicine, in people with recurrent or metastatic (coming back or spread) secretory gland cancers or related salivary gland cancers. It aims to see how well the treatment can shrink tumors and control disease when surgery or radiation is not a cure.
Hear when a new Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.